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ABSTRACT 
The aim of this work was to compare the anti-inflammatory activity of compounds prepared 
from terpenes and the synthetic drugs ibuprofen and naproxen. The anti-inflammatory activity 
of the hybrid compounds was compared with the activity of the parent compounds. This was 
accomplished using in vitro inhibition of LOX and COX-2, and in silico docking studies in 
15-LOX and COX-2. The synthesized hybrids showed an inhibition of COX-2 and LOX 
between 9.8-57.4% and 0.0-97.7%, respectively. None of the hybrids showed an 
improvement in the inhibitory effect towards these pro-inflammatory enzymes, compared to 
the parent terpenes and NSAIDs. The docking studies allowed us to predict the potential 
binding modes of hybrids 6 - 15 within COX-2 and 15-LOX active sites. The relative affinity 
of the compounds inside the binding sites could be explained by forming non covalent 
interactions with most important and known amino acids reported for those enzymes. A good 
correlation (r
2
 =0.745) between docking energies and inhibition percentages against COX-2 
was found. The high inhibition obtained for compound 10 against COX-2 was explained by 
hydrogen bond interactions at the enzyme binding site. New synthetic possibilities could be 
obtained from our in silico models, improving the potency of these hybrid compounds. 
  
1 | INTRODUCTION  
The cyclooxygenases are enzymes that catalyse the two initial steps in prostaglandin 
biosynthesis. Both isoforms of the enzyme, namely COX-1 and COX-2, are targets of 
non-steroidal anti-inflammatory drugs (NSAIDs) 
[1]
. COX-1 is expressed constitutively in 
most cells, while COX-2 is up-regulated by cytokines, shear stress and growth factors. In this 
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of prostanoids formed in inflammation and cancer 
[2]
. A third COX, COX-3, is a splice variant 
of COX-1 that retains enzymatic activity with no clear role up to this point 
[3]
.
   
 
   NSAIDs are inhibitors of COX-2, thus exerting anti-inflammatory effects. The inhibition of 
COX-1 is associated with the undesirable side-effects of these drugs. Therefore, compounds 
with selective COX-2 inhibition are looked-for therapeutic agents 
[4]
. As organic acids, these 
drugs have good bioavailability, have high binding percentages to plasma proteins and are 
accumulated in sites of inflammation. Among NSAIDs, ibuprofen is a widely commercialized 
anti-inflammatory drug with non-selective COX inhibitory effects. The structure of COX-2 
bound to ibuprofen has been elucidated 
[5]
, offering new insights for in silico studies of COX 
inhibitors. Most NSAIDs are organic acids that act by competitive and reversible inhibition of 
COX, with the exception of Aspirin® which irreversible antagonizes the action of COX by 




   Lipoxygenases (LOX) are a family of non-heme iron containing enzymes that catalyse the 
oxygenation of polyenic fatty acids (i.e. arachidonic acid) into the corresponding lipid 
hydroperoxide eicosatetraenoic acids (HPETEs). There are five human lipoxygenases, namely, 
5-LOX, 12(S)-LOX, 12(R)-LOX, 15-LOX and 15-LOX-2, classified according to the site of 
hydroperoxy group insertion and stereoconfiguration 
[7]
. Their expression is frequently cell 
specific, and among them, the 5-LOX pathway leads to the synthesis of leukotrienes (LTs), 
which play a major role in the development and persistence of the inflammatory response. The 
reduction and chelation of the non-heme iron present in the catalytic site of the enzyme is 
proposed as the mechanism of action of 5-LOX inhibitors, such as zileuton 
[9]
. Dual inhibition 





   The three-dimensional X-ray structure of the enzymes COX-2 and LOX has been described. 
These studies allowed in silico experiments in order to understand the intermolecular 
interactions of selected compounds within the binding or active site of these enzymes. For 
instance, the synthesis of Aspirin® analogues as dual COX-2/5-LOX inhibitors was reported 
[9]
. This feature was achieved by incorporating a NO-releasing sulfohydroxamic group 
(SO2NHOH) in the synthetic analogues of the pharmacophore. In vitro COX-1/COX-2 
isozyme inhibition studies identified 2-hydroxysulfamoylbenzoic acid, 
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potent and selective COX-2 inhibitors 
[10]
. Moreover, 2-hydroxysulfamoylbenzoic acid and 
2-hydroxysulfamoylbenzoic acid ethyl ester, with the sulfohydroxamic acid moiety, showed 
potent 5-LOX inhibitory activity. Molecular docking studies in the active binding site of 
COX-2 and 5-LOX provided complementary theoretical support for the experimental 
biological structure-activity data acquired. The synthesis, dual COX/LOX inhibition, 
molecular modeling and cytotoxicity of a series of di-tertiary-butyl phenylhydrazones was 
reported 
[10]
. Molecular docking studies revealed a good fit of these compounds in the COX-2 
and 5-LOX protein cavities.  
 
   The design of hybrid compounds including synthetic moieties and NSAIDs has been 
explored, including the hybrids of Aspirin® 
[11]
, and new compounds including terpene 
moieties 
[12]
. We have previously reported the in vivo anti-inflammatory effect of hybrid 
molecules of terpenes and two synthetic anti-inflammatory agents in the ear edema model in 
mice 
[13]
. However, the activity of these synthetic derivatives on key enzymes associated with 
the inflammatory response is unknown. The aim of the present work was to give an integrated 
interpretation of the biological activity data of the terpenyl esters of ibuprofen and naproxen by 
comparing the information obtained using animal experiments 
[13]
, enzyme inhibition assays 
against COX-2 and LOX and molecular docking studies. 
 
2 | METHODS AND MATERIALS 
2.1. Synthesis 
The starting compounds oleanolic acid, ferruginol and imbricatolic acid were isolated from 
natural sources as previously described 
[13]
. The synthetic anti-inflammatory agents ibuprofen 
and naproxen were racemates from Laboratorio Chile with a purity > 95%. The synthesis of the 




2.2. In vitro inhibition of LOX 
The inhibitory activity of the starting compounds (terpenes and synthetic anti-inflammatory 
drugs) and the hybrid molecules containing the terpene and the synthetic anti-inflammatory 
moieties against lipoxygenase (LOX) was carried out according to 
[14]
. The assay is based on 
the enzymatic oxidation of linoleic acid to its hydroperoxide, which can be measured at 234 nm 
using a Unicam Spectronic (Genesys) spectrophotometer. The only commercially available 
LOX (Type I-B from Glycine max, Sigma L7395) was used for the experiments. Compounds 
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buffer. The 100% activity controls were carried out using DMSO and buffer. The commercial 
NSAIDs ibuprofen and naproxen were used as reference compounds. All compounds were 
evaluated in triplicate and results are expressed as percent of inhibition ± SD. 
 
2.3. In vitro inhibition of COX-2 
The inhibition of COX-2 is based on the potential of the compounds to inhibit the conversion of 
arachidonic acid to prostaglandin H2 (PGH2) by human recombinant COX-2 
[15]
. The assay was 
carried out using a commercial kit (560131, Cayman Chemicals, Ann Arbor, MI, USA), 
following the supplier instructions. Compounds were dissolved in DMSO and diluted to the 
final concentrations (50 µg/mL) using the reaction buffer. The 100% activity controls were 
carried out using DMSO and buffer. PGF2α produced from PGH2 by chemical reduction with 
stannous chloride, was measured in a microplate reader (Biotek ELx 808) at 415 nm. The 
commercial NSAIDs ibuprofen and naproxen were used as reference compounds. All 
compounds were evaluated in triplicate and results are expressed as percent of inhibition ± SD. 
 
2.4. Computational modeling studies 
Molecular docking studies were carried out according to 
[16,17]
. The computational method was 
used in order to suggest the possible binding modes and affinity of the compounds to human 
LOX and COX-2. The molecular docking calculations were carried out using 15-LOX 
isoenzyme considering previous reports on this enzyme and the dual inhibition studies with 
COX-2 
[9,18]
. This isoenzyme has a 42% degree of identity and 62% of similitude with 5-LOX. 
The alignment between the X-ray crystal structures of 5-LOX and 15-LOX is shown in 
supporting information (Supporting Figure 1), showing a RMSD value of only 1.68 Å. 
 
   The atomic coordinates for 15-LOX and COX-2 were obtained from the available X-ray 
crystal structures in Protein Data Bank (PDB) 
[19]
 with codes 4NRE and 4PH9, respectively. 
All X-ray crystal structures were prepared, refined and completed (when needed) using the 
Protein Wizard Preparation module available in Maestro visualization software 
[20]
. All 
compounds were prepared using the software LigPrep 
[21]
, while the protonation states were 
predicted via the Epik program 
[22]
. The analysis was performed using water as a solvent and 
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   Docking experiments were performed using Glide software in standard precision (SP) mode 
[23,24]
. Glide docking uses a series of hierarchical filters to find the best possible ligand binding 
locations in a previously built receptor grid space. The filters include a systematic search 
approach, which samples the positional, conformational, and orientation space of the ligand 
before evaluating the energy interactions between the ligand and the protein. Grid boxes of 30 
Å
3
 and 32 Å
3
 were first centered on the reference ligand co-crystallized with each targeted 
protein (ibuprofen in COX-2 and a substrate-mimic in 15-LOX) and default docking 
parameters were used. Those grid volumes assure an appropriate conformational sampling of 
compounds within the binding sites of studied enzymes and, thereby, a correct interpretation of 
relevant intermolecular interactions between compounds and enzyme residues. The docking 
poses for each ligand were analyzed by examining their relative total energy score. The more 
energetically favorable conformation was selected as the best pose.  
 
2.5. Statistical analyses 
The statistical analyses were carried out using the SPSS 14.0 software (IBM, Armonk, NY, 
USA). Statistically significant differences between samples were determined by one-way 
analysis of variance (ANOVA) followed by Tukey’s multiple comparison test (p = 0.05). 
 
3 | RESULTS 
3.1. Enzyme inhibition activity 




Compounds were tested at 
50 µg/mL against COX-2 and LOX enzymes. The results are summarized in Table 1. 
   In the COX-2 assay, the activity of the starting diterpenes was significantly different for 
imbricatolic acid 2 compared to ferruginol 1 and oleanolic acid 3 (46.2, 29.5 and 32.8%, 
respectively). For the commercial NSAIDs, no significant difference was observed (p < 0.05). 
For the hybrid compounds using ferruginol as the terpene moiety (6 and 7), only the activity of 
the ferruginyl ibuprofenate (6) was significantly lower than the starting compounds. In the 
imbricatoyl derivatives (8-11), the compound imbricatol-15-yl naproxenate (10) showed an 
increase in the COX-2 inhibitory activity compared to the parent compound naproxen (5) (p < 
0.05). Regarding the oleanolic acid derivatives (12-15), oleanoyl ibuprofenate (12) showed the 
highest inhibitory effect of the series, showing better activity than the parent compound 
oleanolic acid (3). In the ibuprofen derivatives, the activity was lower than that of the synthetic 
anti-inflammatory drug alone (57.3%). For the oleanoyl derivatives, the effect of the 
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the COOH function in the triterpene. Interestingly, in the naproxen-oleanolic acid hybrids, the 
methyl ester group at C-28 increased the inhibition of COX-2. 
 
   In the LOX inhibitory assay, among the terpenes, only oleanolic acid (3) showed a marginal 
activity. For the commercial drugs, naproxen presented a 10 fold higher inhibitory effect 
compared to ibuprofen. In the hybrid compounds, all the naproxen derivatives (7, 10, 11, 14 
and 15) inhibited LOX in the range of 81.8-97.7%, which can be attributed to the naproxen 
moiety. Interestingly, oleanoyl ibuprofenate methyl ester (13) showed an increase in the 
inhibitory effect when compared to the parent compounds ibuprofen (4) and oleanolic acid (3).  
 
3.2. Molecular Docking studies 
The molecular docking conformations obtained for all inhibitors within the binding site of 
COX-2 and 15-LOX proteins are shown in Figure 2 and 3. Before the binding pose prediction 
of synthesized ligands against their protein targets, the docking protocol with Glide 
[23] 
was 
validated for each protein-ligand system by predicting the correct pose of X-ray co-crystallized 
ligand within reported protein binding site. In the case of COX-2, the predicted pose for 
ibuprofen was very close to its X-ray crystal structure, with a RMSD value of only 0.244 Å for 
heavy atoms. On the other hand, the best docked pose obtained for substrate mimic in 15-LOX 
deviates in 1.59 Å with respect to its structure in the X-ray crystal structure. Those initial 
docking results gave us confidence that the applied docking protocol with Glide 
[23] 
was 
capable to reproduce the X-ray crystal structure of co-crystalized ligands.   
 
   Figure 2A shows the docked structures of ligand 1 and its ibuprofen and naproxen hybrids 6 
and 7, respectively, within the COX-2 binding site.  
 
   As reference compounds we included: the co-crystallized structure of ibuprofen 
(represented in orange ball and sticks), the docked structures of ibuprofen (4, represented as 
yellow sticks) and naproxen (5, represented as spring green sticks). The carboxylate moiety of 
compounds 4 and 5 established a hydrogen bond (HB) interaction with residues Arg120 and 
Tyr355. The benzyl and naphthalene rings of these reference compounds are located in the 
hydrophobic pocket of COX-2 formed by residues Tyr385, Phe518, Val523 and Ser530 
[8]
. 
These interactions are in good agreement with the report of ibuprofen co-crystallized with 
COX-2 (PDB code: 4PH9) 
[4]
. In the case of compound 1 and its hybrid compounds 6 and 7, 
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establish the same HB interactions with residues Arg120 and Tyr355. Compound 1 is located 
in the same pocket as ibuprofen and naproxen but establishes only hydrophobic interactions 
with the residues at this site. Compounds 6 and 7 are located outside the pocket, establishing 
some π-stacking interactions with aromatic side chains of residues Tyr115 and Tyr355. The 
low percentages of in vitro inhibition shown by these compounds against COX-2 (22.2 and 
32.2%, respectively) could be explained by: its relative big size to accommodate in the 
hydrophobic pocket, the lack of the carboxylate group (terpene 1) and mostly by the hindered 
ester moiety that cannot establish HB interactions within the binding site (hybrids 6 and 7). 
 
   Figure 2B depicts the docked poses for compounds 2, 8 - 11 within the COX-2 binding site. 
The carboxylate moiety of terpene 2 forms two HBs with residue Arg120 and one additional 
HB with Tyr355, resembling those interactions formed by reference compounds 4 and 5. The 
diterpene moiety is located in the same pocket as the reference compounds, establishing 
hydrophobic interactions with residues Tyr385, Phe518, Val523 and Ser530. Compounds 8, 9, 
10 and 11 were able to establish HB interactions with residue Arg120 through the carbonyl 
group in the ester moiety that is less hindered that in compounds derived from terpene 1. The 
benzyl and naphthalene rings in these compounds are located within the COX-2 binding in the 
same orientation that reference compounds 4 and 5. An additional HB interaction is established 
by compounds 10 and 11 with residue Tyr355. The imbricatol moiety in all these derivatives is 
oriented towards the outer part of the binding pocket, probably establishing hydrophilic 
interactions with water. The improved inhibition percentages against COX-2 showed by these 
derivatives could be rationalized in terms of availability of their carbonyl ester to establish HB 
interactions with residues at COX-2 binding site. In addition, the ibuprofen and naproxen 
moieties of these hybrids show the same orientation as the reference compounds. 
 
   Figure 2C shows the best docking poses for compounds 3, 12 - 15. The size of these 
derivatives may suggest that they cannot fit within the COX-2 binding site. Instead, they could 
interfere with the enzyme function by blocking the entrance of the natural substrate to the 
binding pocket from different sides. No docking pose was obtained for compound 12, thus 
suggesting that the high inhibition percentage against COX-2 (Table 1) may be achieved 
through another molecular mechanism like allosteric regulation or hindrance of the binding site 
entrance 
[25]
. Compound 3, 13 and 14 block the entrance to the main pocket of COX-2 in 
different extents. Compound 15 seems to block a second pocket that gives access to some 
ligands for the interaction with residues Arg513 and His90 
[9]
. A good correlation (r
2
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was obtained when comparing the COX-2 inhibition percentages and the relative docking 
energies calculated for compounds 1 - 15 (Table 2). The structural alignment between X-ray 
crystal structures for LOX-5 and LOX-15 and data plot for correlation between COX-2 
percentage of inhibition and Glide docking score relative energy (kcal/mol) for studied 
compounds can be found in the Supporting Figure 1 and 2, respectively. 
 
   Figure 3 shows the docked structures of ligands 1-15 within the 15-LOX binding site. The 
binding site of 15-LOX is near the Fe
3+ 
metal that is coordinated by residues Ile676, His373, 
His378 and His553 (Figure 3A). Two water molecules in the crystal structure complete the 
coordination sphere, but they were deleted in order to perform the docking calculations. 
Hydrophobic residues Leu420, Leu610, Ile412 and the solvent exposed residue Arg429, 
complete this binding pocket. The co-crystallized substrate-mimic (orange balls and sticks) fits 
in a U-shape form within the binding site, mostly establishing hydrophobic interactions with 
the above mentioned residues.  
 
   Docked structures of ibuprofen (4, yellow sticks) and naproxen (5, spring green sticks), are 
coordinating the iron atom through one of their oxygen carboxylate atoms (with distances 
about 2.2 Å). Their benzyl and naphthalene rings are located in the inner part of the pocket 
when compared with the substrate mimic.  
 
   Compounds 1, 6 and 7 docked in the outermost and solvent exposed part of the binding 
pocket, establishing some hydrophobic interactions through their terpene rings. The ibuprofen 
and naproxen moieties of compounds 6 and 7 are oriented to the solvent. In addition, 
compound 6 establishes an HB interaction with residue Arg429. 
 
4| DISCUSSION 
4.1. Enzyme inhibition activity 
When comparing the in vitro enzyme inhibitory activity of compounds 1-15 with that observed 
for the same derivatives in the topic anti-inflammatory model in the mice ear edema 
[13]
, several 
differences were found. The arachidonic acid (AA)-induced ear edema is associated with the 
inhibition of COX-1 and COX-2, while the phorbol 12-myristate 13-acetate (TPA)-induced 
topical inflammation is associated with LOX as main mechanism. In the in vivo experiments 
(expressed as percent inhibition compared with untreated controls), ferruginol 1 was active in 










This article is protected by copyright. All rights reserved. 
naproxen showed marginal activity (7.2 and 1.8%, respectively). However in the in vitro tests, 
compound 1 was less active than 4 and 5 in the COX-2 assay. Considering the hybrid 
compounds, it was reported 
[13]
, that compound 12 reduced by 56.8% the inflammation induced 
by AA. In the in vitro experiments, the same compound showed the highest inhibition activity 
against COX-2, while 10 and 15 were active against COX-2 but inactive in the in vivo 
experiments. The compound 12 was active both in the AA-induced ear edema and COX-2 in 
vitro inhibition.  
 
   When comparing the in vivo TPA model with the in vitro inhibition of LOX a similar effect 
was observed for the terpenes, being oleanolic acid (3) the most active in both assays (70.2 and 
6.6%, respectively). On the contrary, naproxen (5) displayed low activity in the in vivo model, 
while the highest inhibitory effect in the in vitro studies (29.9 and 98.4%, respectively). In the 
in vivo experiments, terpenes and synthetic anti-inflammatory compounds were compared at 
the same equimolar dose. The compounds were applied topically at 1.4 and 3.2 µmol/mouse 
for 12-O-tetradecanoyl phorbol 13-acetate and the arachidonic acid assay, respectively 
[13]
. 
Meanwhile, in the in vitro experiments the compounds were assayed at a single concentration 
of 50 µg/mL, which equates to 70-105 µM for the hybrid compounds. 
 
   A strong effect in the TPA-induced ear edema was observed for oleanoyl ibuprofenate 
(compound 12, 79.9%), and oleanoyl naproxenate methyl ester (compound 15, 80.0%), in the 
same range as the starting diterpene oleanolic acid (compound 3, 70.2%) and higher than 
ibuprofen 4 (56.2%) 
[26]
. However, in the in vitro LOX inhibition only compound 15 showed 
the same activity (Table 1). 
 
   In summary, when comparing the results in the in vivo models of inflammation and COX-2 
inhibition, the most active compound was oleanoyl ibuprofenate 12 in both models; while for 
the in vitro LOX and TPA-induced edema in the mice ear, the best effect in both systems was 
for the oleanoyl naproxenate 14 and its methyl ester 15. 
 
4.2. Molecular Docking studies 
Figure 3B shows the most probable docked poses for compounds 2, 8 - 11 within 15-LOX 
binding site. Imbricatolic acid (2) binds at the entrance of the binding pocket forming two HBs 
with residues Arg429 and Ile420. Compounds 8, 9, 10 and 11 can bind in the same orientation 
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these compounds can coordinate the iron atom through their carbonyl groups at the ester 
moiety with distances between 2.77 to 3.18 Å. This finding could positively impact their 
capability to inhibit the enzyme when compared with those in ibuprofen or naproxen. 
However, the good fit of the naphthalene ring within the binding site and some HB interactions 
with residue Arg429 at the entrance of the pocket, could also be responsible for the good 
inhibitory activities shown by compounds 10 and 11. For compounds 8 and 9, despite that the 
benzyl rings also fit within the pocket, the orientation of the diterpene rings toward the solvent 
channel could negatively impact their desolvation entropic energy, thus penalizing their 
capability to effectively inhibit 15-LOX. 
 
   Figure 3C shows the most probably docking poses for compounds 3, 12 - 15. Oleanolic acid 
(3) cannot bind inside the 15-LOX binding site and, instead, it locates at the entrance of the 
pocket where it is mostly exposed to the solvent. On the other hand, compounds 12 and 13 also 
bind at the entrance of the 15-LOX binding pocket with their ibuprofen benzyl rings orientated 
to the iron atom, but incapable to form any stabilizing interaction with key residues at this site. 
This could explain their low and null inhibitory activities against this enzyme, respectively. 
Compounds 14 and 15, bind at the entrance of the binding pocket, however, their stabilization 
is due to π-cation interactions between naproxen naphthalene rings and the charged residue 
Arg429. Compound 14 establishes an additional interaction with Arg429 through an HB which 
is mediated by a carbonyl group in its ester moiety. Those stabilizing non-covalent interactions 
could be responsible for their inhibitory activity against 15-LOX by blocking the binding 
pocket.   
 
   No significant correlation was found between docking energy (Table 2) and percentage of 
inhibition against 15-LOX. However, their inhibitory patterns could be explained by the 
structural interpretation of the conformations obtained with the molecular docking within the 
enzyme binding site. The binding site of 15-LOX seems to be flexible, as other 
macromolecular targets, and there is previous evidence that some induced fit docking protocols 
are needed in order to obtain good relationships between biological activity and docking 
energies, or most accurate, free binding energy methods for active ligands 
[26]
.
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5| CONCLUSIONS 
The synthesized hybrids showed an inhibition of COX-2 in the range of 9.8-57.4%. The LOX 
inhibition was in the range of 0-97.7%. None of the hybrids compounds showed an 
improvement in the inhibitory effect towards these pro-inflammatory enzymes, compared to 
the parent terpenes and commercial NSAIDs. However, the hybrids 7, 11 and 15 showed strong 
inhibitory activity towards LOX and moderate inhibitory effect against COX-2. The molecular 
docking studies allowed us to predict the potential binding modes of hybrid molecules 1 - 15 
within COX-2 and 15-LOX active sites. Moreover, the relative affinity of those compounds 
inside the binding sites could be explained in terms of their stabilization by forming non 
covalent interactions, like hydrogen bonds, -stacking, -cation and van der Waals, with most 
important and known amino acids reported for those proteins. A good correlation (r
2
 =0.745) 
between molecular docking energies and percentage of inhibition showed by compounds 
against COX-2 enzyme was found. New synthetic possibilities could be obtained from our in 
silico models, aiming to improve the potency of this series of hybrid compounds.  
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FIGURE LEGENDS 
 
FIGURE 1 Structure of the starting natural terpenes (1-3), synthetic 
anti-inflammatory drugs (4-5) and the ibuprofenyl and naproxenyl esters 6-15. 
 
FIGURE 2 Most probable conformations of compounds 1 - 15 within the COX-2 
binding site. Protein carbon atoms are colored in gray and represented in balls and sticks. 
Non polar hydrogen atoms are not shown. Co-crystalized ibuprofen is represented as 
orange balls and sticks. Reference compounds 4 and 5 are represented as yellow and 
spring green sticks, respectively. Compounds 1, 2 and 3 are represented in red thin sticks; 
compounds 6 and 8 are colored in blue; compounds 7, 9 and 13 are colored in purple; 
compounds 8, 10 and 14 are colored in dark green and compounds 9, 11 and 15 are 
colored in plum. Hydrogen bond and π-stacking interactions are represented as yellow and 
cyan dashed lines, respectively. A) Docked poses of compounds 1, 6, 7; B) Docked poses 
of compounds of compounds 2, 8-11; C) Docked poses for compounds 3, 12-15. 
 
FIGURE 3 Most probable conformations of compounds 1 - 15 within 15-LOX 
binding site. Protein carbon atoms are colored in gray and represented in balls and sticks. 
Non polar hydrogen atoms are not shown. Co-crystalized substrate mimic is represented 
as orange balls and sticks and the iron atom is depicted in black. Reference compounds, 
4 and 5, are represented as yellow and spring green sticks, respectively. Compounds 1, 2 
and 3 are represented in red thin sticks; compounds 6, 8 and 12 are colored in blue; 
compounds 7, 9 and 13 are colored in purple; compounds 8, 10 and 14 are colored in 
dark green and compounds 9, 11 and 15 are colored in plum. Hydrogen bond and 
cation-π interactions are represented as yellow and green dashed lines, respectively. A) 
Docked poses of compounds 1, 6, 7; B) Docked poses of compounds of compounds 2, 
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TABLE 1  Percent inhibition of the terpenes (1-3), the synthetic anti-inflammatory 
drugs ibuprofen (4), naproxen (5) and the diterpenyl esters of ibuprofen and naproxen 
6-15 on the enzymes COX-2 and LOX at 50 µg/ml.  




Ferruginol (1) 29. 5 ± 7.1
a 
Inactive 
Imbricatolic acid (2) 46.2 ± 3.3
b,h,i 
Inactive 
Oleanolic acid (3) 32.8 ± 2.5
a,c,d
 6.60 ± 0.6
a 
Ibuprofen (4) 57.3 ± 6.0
b,h,i 
 9.8 ± 0.6
a 












Imbricatol-15-yl ibuprofenate (8) 9. 8 ± 0.8
g 
Inactive 
Imbricatol-15-yl ibuprofenate methyl ester (9) 44.8 ± 3.8
b,c,i 
Inactive 








Oleanoyl ibuprofenate (12) 56.3 ± 5.1
b,h,i 
Inactive 













Different letters in the same column show significant differences within each compound, according to 
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TABLE 2    Glide docking score energies for the studied compounds against 




Glide SP Emodel  
(kcal/mol) 
Glide SP Emodel  
(kcal/mol) 
1 -23.60 -35,09 
2 -52.67 -45,20 
3 -15.97 -48,08 
4 -65.46 -63,87 
5 -76.57 -68,91 
6 -16.89 -44,49 
7 -4.52 -35,08 
8 -56.52 -93,91 
9 -53.77 -93,50 
10 -79.89 -90,25 
11 -59.91 -98,40 
12 n/d -61,87 
13 -25.37 -55,59 
14 -32.90 -63,05 
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